Arlene Chapman to Risk Factors
This is a "connection" page, showing publications Arlene Chapman has written about Risk Factors.
Connection Strength
0.402
-
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
Score: 0.074
-
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012 Mar; 7(3):479-86.
Score: 0.050
-
Polycystic kidney disease: The cadence of kidney growth in ADPKD. Nat Rev Nephrol. 2009 Jun; 5(6):311-2.
Score: 0.041
-
Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass. Am J Nephrol. 2021; 52(2):173-176.
Score: 0.023
-
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652.
Score: 0.019
-
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. J Am Heart Assoc. 2018 03 09; 7(6).
Score: 0.019
-
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018 03; 93(3):691-699.
Score: 0.019
-
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469.
Score: 0.018
-
Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120.
Score: 0.017
-
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol. 2016; 44(2):130-40.
Score: 0.017
-
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014 Nov 10; 3(6):e001398.
Score: 0.015
-
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014 Feb; 34(2):123-30.
Score: 0.014
-
Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013; 8(3):e57639.
Score: 0.013
-
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar; 81(6):577-85.
Score: 0.012
-
Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2508-15.
Score: 0.012
-
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Mar; 6(3):640-7.
Score: 0.011
-
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010 Feb; 31(2):440-6.
Score: 0.011
-
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006 Mar; 17(3):854-62.
Score: 0.008
-
Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 May; 63(5):1824-30.
Score: 0.007